Andreas Kuhn | Vice President
BioNTech Ag

Andreas Kuhn, Vice President, BioNTech Ag

Andreas Kuhn has worked in the field of RNA biochemistry and molecular biology for more than thirty years. His work on RNA-based immunotherapies began in 2007 in the academic group of Ugur Sahin at the University Clinic Mainz, and Andreas joined BioNTech RNA Pharmaceuticals GmbH shortly after its founding in 2008. In his current role as Senior Vice President RNA Biochemistry & Manufacturing the main focus is expanding proprietary technologies to increase the efficacy of RNA-based therapies and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored numerous publications and patents ranging from basic research on RNA to its application as a diagnostic and therapeutic agent.

Appearances:



Day 3, September 30th @ 13:40

Interactive panel: Unique rapid production opportunities and challenges that face nucleic acid-based vaccine manufacture and delivery

  • Why and where will it make a difference?
  • How is it different to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like SARS-CoV-2? Can the scale-up/volume be big enough?
  • Does the speed and dosage have an effect on the overall quality of the vaccine?
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT

back to speakers